① SUNNY OPTICAL's onboard camera shipment in May increased by about 30%. How did the mobile business perform? ② CHOW TAI FOOK reported a revenue of nearly 90 billion yuan in the last fiscal year. What was the profitability situation?
Cailian Press, June 12 (Editor: Feng Yi) brings you today's important announcements from the Hong Kong stock market.
1) Company news
SUNNY OPTICAL (02382.HK): The shipment volume of mobile camera lenses in May was 98.099 million units, a year-on-year decrease of 5.2%; the onboard camera shipment volume was 10.706 million units, a year-on-year increase of 28.4%; the shipment volume of mobile camera modules was 37.729 million units, a year-on-year decrease of 17.1%.
The announcement stated that the year-on-year increase in the shipment volume of Onboard Cameras was mainly due to the rise in demand from clients. The year-on-year decline in the shipment volume of smartphone camera modules was mainly due to the company's focus on mid-to-high-end projects, and the product structure has significantly improved compared to the same period last year.
NEW CHINA LIFE INSURANCE (01336.HK): Plans to invest no more than 15 billion yuan (inclusive) to subscribe to the third phase of private equity fund shares. The fund will have a duration of 10 years and is an equity-type private securities investment fund, with investments in large listed companies A+H shares that meet the criteria in the constituents of the CSI A500 Index.
CHOW TAI FOOK (01929.HK): Released full-year results ending March 31, 2025, with a turnover of 89.656 billion HKD, a year-on-year decrease of 17.53%; net income was 5.916 billion HKD, a year-on-year decrease of 8.97%.
Additionally, from April 1 to May 31, 2025, CHOW TAI FOOK's sales value decreased by 1.7% year-on-year, among which, retail sales in mainland China decreased by 2.9% year-on-year, while retail sales in Hong Kong, Macau, and other markets increased by 6.3% year-on-year.
JBM HEALTHCARE (02161.HK): Released annual performance for the year ending March 31, 2025, with revenue of 0.782 billion HKD, an increase of 20.65% year-on-year; net income of 0.197 billion HKD, an increase of 51.2% year-on-year.
CHINNEY INV (00216.HK): Issued a profit warning, expecting a net loss attributable to shareholders of approximately 0.56 billion to 0.58 billion HKD for the year.
YIDA CHINA (03639.HK): Cumulative contract sales in the first five months reached 0.359 billion yuan, a year-on-year decrease of 1.1%; sales in May totaled 0.036 billion.
HBM HOLDINGS-B (02142.HK): Wholly-owned subsidiary Nonna Biotech (USA) has entered into a licensing agreement with Visterra, Inc. to utilize Nonna Biotech's proprietary Human-Only Heavy Chain Antibody (HCAb) Harbour Mice technology platform to advance Visterra's next-generation immunotherapy and autoimmune disease biopharmaceutical pipelines.
The announcement indicates that this technology platform can generate fully human-only heavy chain antibodies, possessing key advantages such as reduced immunogenicity and enhanced multi-functionality of next-generation biopharmaceutical products. This innovative platform has been clinically validated and widely recognized by global partners.
2) Buyback dynamics.
TENCENT (00700.HK): Invested 0.5 billion HKD to repurchase 0.975 million shares, with a repurchase price of 508-518 HKD per share.
HSBC Holdings (00005.HK): Invested 0.102 billion HKD to repurchase 1.0892 million shares, with a repurchase price of 93.15-93.9 HKD.
AIA (01299.HK): Invested 44.9605 million Hong Kong dollars to repurchase 0.65 million shares at a repurchase price of 68.75-69.6 Hong Kong dollars.
SHANGHAI PECHEM (00338.HK): On June 12, 2025, will cancel a total of 36.264 million H shares that have been repurchased.
